Laserfiche WebLink
shall have the opportunity to discuss the results with the MRO. If the employee does not discuss the <br /> results of the positive urine drug test with the MRO within 72 hours after being contacted,or refuses the <br /> opportunity to do so,the MRO shall proceed with the positive verification. <br /> Section 6 Sample Collection <br /> The collection and testing of samples shall be performed only by a laboratory and by a physician or health <br /> care professional qualified and authorized to administer and determine the meaning of any test results. <br /> The laboratory performing the test shall be one that is certified by the National Institute of Drug Abuse <br /> (NIDA). <br /> Collection of blood or urine samples shall be conducted in a manner which provides for the highest, <br /> reasonable degree of security for the sample and freedom from adulteration. Blood or urine samples will <br /> be submitted as per NIDA standards including the recognized chain of custody procedures. Employees <br /> have the right for Union representation to be present. Employees shall not be witnessed while submitting <br /> a urine specimen. Prior to submitting to a urine or blood sample,the employee will be required to sign a <br /> consent and release form as attached to this Article. <br /> A split sample shall be reserved in all cases for an independent analysis in the event of a non-negative <br /> specimen. All samples must be stored in a scientifically acceptable preserved manner as established by <br /> NIDA.All positive confirmed samples and related paperwork must be retained by the laboratory for at <br /> least six(6)months or for the duration of any grievance,disciplinary action,or legal proceedings, <br /> whichever is longer.At the conclusion of this period,the laboratory's paperwork and specimen shall be <br /> destroyed.Tests shall be conducted in a manner to ensure that an employee's legal drug use and diet does <br /> not affect the test result. <br /> Section 7 Drug Testing <br /> The laboratory shall test for only the substances and within the limits as follows for the initial and <br /> confirmatory test as provided within NIDA standards.The initial test shall use an immunoassay test <br /> procedure,which meets the requirements of the Food and Drug Administration for commercial <br /> distribution.The following initial cutoff levels shall be used when screening specimens to determine <br /> whether they are negative for these five drugs or classes of drugs: <br /> INITIAL TESTING: <br /> Marijuana (by blood draw) <br /> Cocaine metabolites 150 ng/ml <br /> Opiate metabolitesl 2000 ng/ml <br /> Phencyclidine 25 ng/ml <br /> Amphetamines <br /> AMP/MAMP 500 ng/ml <br /> MDMA500 ng/ml <br /> (1) If immunoassay is specific for free morphine, the initial test level is 25 ng/ml. <br /> If initial test results are negative,testing shall be discontinued,all samples destroyed and records of the <br /> testing expunged from the employee's files.Only specimens identified as positive on the initial test shall <br /> be confirmed using gas chromatography/mass spectrometry(GC/MS)techniques at the following listed <br /> cutoff values. <br /> 54 <br />